Status
Completed
Phase
Phase 1
Enrollment
28
Locations
1
Results
Not posted
Publications
0
Study summary
This trial is conducted in china. The aim of the trial is as follows: * To assess the effect of multiple subcutaneous injections of JY09 injection on the pharmacokinetic (PK) profile of multiple oral doses of metformin hydrochloride tablets, a single oral dose of Rosuvastatin calcium tablets, or digoxin tablets in overweight Chinese subjects; * To assess the effect of multiple subcutaneous injections of JY09 injection on QT interval in overweight Chinese subjects.
Interventions
DRUG
D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
DRUG
D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
DRUG
D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
DRUG
D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
Timeline
First posted
Feb 8, 2024
Study start
Oct 19, 2023
Primary completion
Apr 15, 2024
Study completion
Apr 15, 2024
Results posted
Not reported
Registry updated
Aug 21, 2024
Outcomes
The Metformin Peak Concentration (Cmax )
Time frame · During a dosing interval (0-36 hours) after the last of 7 repeated doses of metformin without JY09 exposure (Day 4) and at JY09 steady state (Day 88)
The peak concentration(Cmax） is the highest level of plasma concentration that occurs after administration.This parameter is an important index to reflect the absorption rate and degree of drug in vivo.
Area under the Metformin blood concentration-time curve
Time frame · During a dosing interval (0-36 hours) after the last of 7 repeated doses of metformin without JY09 exposure (Day 4) and at JY09 steady state (Day 88)
AUC refers to the area under the drug time curve, which is the area surrounded by the pharmacokinetic blood concentration curve to the time axis. This parameter is an important index to evaluate the degree of drug absorption, reflecting the exposure characteristics of drugs in vivo.
The Rosuvastatin Peak Concentration (Cmax )
Time frame · From time 0 to 96 hours after a single dose of Rosuvastatin without JY09 exposure (Day 8) and at JY09 steady state (Day 95)
The peak concentration(Cmax） is the highest level of plasma concentration that occurs after administration.This parameter is an important index to reflect the absorption rate and degree of drug in vivo.
Area under the Rosuvastatin blood concentration-time curve
Time frame · From time 0 to 96 hours after a single dose of Rosuvastatin without JY09 exposure (Day 8) and at JY09 steady state (Day 95)
Area under curve(AUC) refers to the area under the drug time curve, which is the area surrounded by the pharmacokinetic blood concentration curve to the time axis. This parameter is an important index to evaluate the degree of drug absorption, reflecting the exposure characteristics of drugs in vivo.
The Digoxin Peak Concentration (Cmax )
Time frame · From time 0 to 168 hours after a single dose of Digoxin without JY09 exposure (Day 15) and at JY09 steady state (Day 102)
The peak concentration(Cmax） is the highest level of plasma concentration that occurs after administration.This parameter is an important index to reflect the absorption rate and degree of drug in vivo.
Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection
Time frame · From time 0 to 72 hours after a single dose of JY09 (Day 22) and at JY09 steady state (Day 92)
Corrected QT interval is a QT interval adjusted by heart rate, which is an index of cardiac depolarization and repolarization
Safety endpoint-Adverse events
Time frame · From baseline (Day -1) to follow-up (Day 123)
All adverse medical events occurring after the subject receives the experimental drug, which may be manifested as symptoms, signs, diseases, or abnormalities in laboratory tests, but may not necessarily have a causal relationship with the experimental drug.
Vital signs-Blood pressure
Time frame · From baseline (Day -1) to follow-up (Day 123)
Blood pressure includes systolic and diastolic blood pressure.
Vital signs-Pulse
Time frame · From baseline (Day -1) to follow-up (Day 123)
Pulse refers to the pulsation formed in the arteries when the heart contracts, due to the flow of blood from the heart into the arteries. Pulse is one of the vital signs of human body, and it is an important index to measure heart rate and blood pressure.
Vital signs-Respiration
Time frame · From baseline (Day -1) to follow-up (Day 123)
Respiration refers to the process of gas exchange between the body and the outside world.
Physical examination
Time frame · From baseline (Day -1) to follow-up (Day 123)
Include general condition, skin, neck (including thyroid), head (including eyes, ears, nose, throat), chest, abdomen, back, lymph nodes, limbs, and nervous system.
Laboratory tests-Routine blood
Time frame · From baseline (Day -1) to follow-up (Day 123)
Blood routine refers to the examination of blood conditions and diseases by observing the changes in the number and morphological distribution of blood cells.
Laboratory tests-Blood biochemistry
Time frame · From baseline (Day -1) to follow-up (Day 123)
Blood biochemical examination can determine the content of sugars, lipids, hormones, ions and other substances in the blood, and provide help for the diagnosis and treatment of diseases.
Laboratory tests-Urine routine
Time frame · From baseline (Day -1) to follow-up (Day 123)
Urine routine is of great significance not only for the observation of the curative effect of the diagnosis of urinary system diseases, but also for the diagnosis and prognosis of other system diseases.
Laboratory tests-coagulation function
Time frame · From baseline (Day -1) to follow-up (Day 123)
The coagulation function test is mainly to find out whether the clotting factors in the patient's body are abnormal.
12-lead electrocardiogram (ECG)
Time frame · From baseline (Day -1) to follow-up (Day 123)
Electrocardiogram (ECG) is an objective index of the occurrence, propagation and recovery of cardiac excitation. It is used for the examination of various arrhythmias, ventricular and atrial hypertrophy, myocardial infarction, arrhythmia, myocardial ischemia and other diseases.
Eligibility
Inclusion Criteria: 1. Age: Overweight subjects with full capacity for civil behavior who are ≥ 18 years old and ≤ 45 years old (the ratio of the number of subjects of either sex is not less than 1/3). 2. Body weight: men ≥ 50.0 kg, women ≥ 45.0 kg, body mass index (BMI) ≥ 24.0 kg/m2 and ≤ 28.0 kg/m2 , BMI = weight (kg)/height (m2 ). 3. Those who do not plan to have children in the last 6 months, do not plan to donate sperm/eggs, and are willing to use effective contraception for 6 months after the end of dosing. 4. Fully understand the trial and possible adverse effects, have the ability to communicate normally with the investigator, as well as comply with study requirements, follow protocol procedures and limitations, and be able to visit on time. 5. Understand the content of the informed consent form, agree to participate in this trial and voluntarily sign the consent form. Exclusion Criteria: 1. A clear history of central nervous system, cardiovascular system, renal, hepatic, pulmonary, metabolic, and musculoskeletal disorders or other notable diseases. 2. Individuals with gastrointestinal disorders, such as history of hepatobiliary disease, history of gastrointestinal disease, history of gastrointestinal surgery (except appendectomy) or history of chronic pancreatitis or idiopathic acute pancreatitis, and those with habitual diarrhea. 3. Previous tip-twisting ventricular tachycardia or other risk factors that can lead to malignant arrhythmias, or a family history of first-degree relatives (i.e., biological parents, siblings, or children) with short QT syndrome, long QT syndrome, unexplained sudden death, drowning, or sudden infant death syndrome in young adulthood (less than/equal to 40 years of age), or cardiac conduction block. 4. Have disorders of electrolyte metabolism such as hyperkalemia, hypokalemia, hypomagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia. 5. If the results of vital signs (blood pressure, pulse, respiration, temperature) are abnormal and clinically significant, a retest is allowed to confirm the results if they are abnormal, and the abnormal values of each vital sign. 6. Physical examination, laboratory tests, 12-lead electrocardiogram (ECG), abdominal ultrasound, calcitonin and chest radiographs (orthopantomograms) suggesting the presence of abnormalities judged by the investigator to be clinically significant (retesting was allowed once). 7. Smokers who smoked an average of more than 5 cigarettes per day in the 3 months prior to screening or who could not give up smoking during their participation in the trial or who had a positive smoke test. 8. Those who have participated in other clinical trials as a subject within 3 months prior to screening. 9. Those who donated blood or blood products ≥400 mL within 3 months prior to screening. 10. Those who cannot tolerate venipuncture and have a history of needle and blood sickness.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Peking University Third Hospital drug clinical trial Institute
Beijing, Beijing Municipality, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
Chinese University of Hong Kong · Cerebral Small Vessel Disease
Phase 2
Recruiting
110
2026-06
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.